QLT, Inc. (USA) (NASDAQ:QLTI)

following Eliav Assouline and Marc Andersen's hedge fund Axial Capital Management

QLT's ascent seems to have stuttered at about the 4.75 level although it remains close to its year high. Their only marketed product, Visudyne, is a niche ophthalmologic medication with declining revenues. They will continue to receive revenue from the Eligard sale but this is already baked into the market cap. I detect undercurrents of efficacy issues with the Punctum plug program. The only other short-term catalysts will be data from the DENALI and RADICAL studies of Visudyne, which I don't expect to reverse the decline of that product. The cash position is admittedly strong, but nothing has justified the recent rise in price for this historically weak stock.